FEATURED LINKS
Vical at NASDAQ Closing Bell Ceremony May 25
Vijay Samant Interview on BioBusiness.TV May 25
CLINICAL TRIALS
Click below to learn more about current Vical clinical trials for specific cancer and infectious disease applications.
INVESTOR INFO
| NASDAQ: VICL | |
WELCOME TO VICAL
Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Our independent programs include the Allovectin-7® immunotherapy for metastatic melanoma, the vaccine to prevent cytomegalovirus reactivation in hematopoietic stem cell transplant patients, and vaccines for pandemic influenza.
VAXFECTIN®
Vical's proprietary Vaxfectin® adjuvant for vaccines has demonstrated safety and effectiveness in a number of animal models and was successfully tested in a Phase 1 human trial against H5N1 pandemic influenza. References to published data are included in the Vaxfectin® Publications page.